Breaking News

Tweet TWEET

Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium

Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio
                           Breast Cancer Symposium

PR Newswire

WOODCLIFF LAKE, N.J., Nov. 28, 2012

WOODCLIFF LAKE, N.J., Nov. 28, 2012 /PRNewswire/ --Eisai Inc. announced today
that six abstracts highlighting new study results will be presented during the
2012 CTRC-AACR San Antonio Breast Cancer Symposium. The meeting will be held
December 4-8, 2012 at the Henry B. Gonzalez Convention Center in San Antonio,
TX.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

These studies highlight Eisai's current and ongoing clinical research efforts
with Halaven^® (eribulin mesylate) Injection, reinforcing the company's
commitment to the breast cancer community. Additionally, Phase III study
results of the head-to-head study of eribulin vs. capecitabine will be
highlighted as part of a SABCS-sponsored news conference to be held on
December 7, 2012.

"As part of our human health care mission we strive to better understand the
needs of patients and their families to help increase the benefits that
healthcare provides," said Kenichi Nomoto, Ph.D., President, Oncology Product
Creation Unit at Eisai. "Our continued work to further understand the clinical
profile of eribulin underscores our commitment to this important mission."

The following Eisai abstracts are accepted for presentation at this year's San
Antonio Breast Cancer Symposium:

Product           Abstract Name
Eribulin Mesylate A Phase III, open-label, randomized, multicenter study of
                  eribulin mesylate versus capecitabine in patients with
Session:          locally advanced or metastatic breast cancer previously
                  treated with anthracyclines and taxanes
S6-6
                  Oral Presentation
Eribulin Mesylate Results of a Phase II, multicenter, single-arm study of
                  eribulin mesylate as first-line therapy for locally
Abstract No:      recurrent or metastatic HER2-negative breast cancer

P1-12-02          Poster Session
Eribulin Mesylate Eribulin mesylate + trastuzumab as first-line therapy for
                  locally recurrent or metastatic HER2-positive breast cancer:
Abstract No:      results from a Phase II, multicenter, single-arm study

P5-20-04          Poster Session
Eribulin Mesylate Adjuvant treatment of early-stage breast cancer with
                  eribulin mesylate following dose-dense doxorubicin and
Abstract No:      cyclophosphamide: preliminary results from a Phase II,
                  single-arm feasibility study
P1-13-11
                  Poster Session
Eribulin Mesylate Post-hoc safety and tolerability assessment in patients
                  receiving palliative radiation during treatment with
Abstract No.      eribulin mesylate for metastatic breast cancer

P6-11-14          Poster Session
N/A               Family Members' Burden in Patients with Metastatic and Early
                  Stage Breast Cancer
Abstract No:
                  Poster Session
P6-09-06

The information discussed in this release is about investigational uses for an
FDA-approved product. It is not intended to convey conclusions of efficacy and
safety.

About Halaven
Halaven is indicated for the treatment of patients with metastatic breast
cancer who have previously received at least two chemotherapeutic regimens for
the treatment of metastatic disease. Prior therapy should have included an
anthracycline and a taxane either in the adjuvant or metastatic setting.

Important Safety Information about Halaven

Decreased White Blood Cells (Neutropenia)
A doctor should do a blood test to monitor a patient's blood cells before they
receive each dose of Halaven, and should monitor them more often if they
develop lower white blood cells. If a patient develops severe neutropenia
lasting longer than 7 days or neutropenia with a fever, their next dose of
Halaven should be delayed and reduced. Severe neutropenia occurred in 57%
(287/503) of patients who received Halaven and lasted more than 1 week in 12%
(62/503) of patients. Neutropenia with a fever occurred in 5% (23/503) of
patients; 2 patients died from complications of neutropenia with a fever.
Neutropenia with a fever can result in serious infections that could lead to
hospitalization or death. Patients should call their healthcare provider
immediately if they have any of the following symptoms: fever (temperature
above 100.5degrees F), chills, coughing, burning or pain when they urinate.

Nerve Disorders (Peripheral Neuropathy)
Halaven can cause numbness, tingling, or burning in a patient's hands and feet
(peripheral neuropathy). A patient should be monitored closely for signs of
neuropathy. If a patient develops severe neuropathy, treatment with Halaven
should be delayed until the neuropathy improves and the next dose of Halaven
should be reduced. Severe peripheral neuropathy occurred in 8% (42/503) of
patients who received Halaven. Neuropathy lasting more than one year occurred
in 5% of patients. Twenty-two percent (109/503) of patients developed a new or
worsening neuropathy that had not recovered after an average of 269 days.
Peripheral neuropathy was the most common side effect that caused patients to
stop receiving Halaven.

Pregnancy and Nursing
Halaven may harm a patient's unborn baby. A patient should avoid becoming
pregnant while they are receiving Halaven. A patient should tell their
healthcare provider right away if they become pregnant or think they are
pregnant while they are receiving Halaven. The patient and their healthcare
provider should decide if they will receive Halaven or breastfeed. A patient
should not do both.

Heartbeat Changes
Halaven can cause changes in a patient's heartbeat (called QTc prolongation).
This can cause irregular heartbeats that may lead to death. A patient's
healthcare provider will decide if they need heart monitoring
(electrocardiogram or ECG), or blood tests during their treatment with Halaven
to watch for this problem.

Liver and Kidney Problems
In patients with mild or moderate liver problems, and/or moderate kidney
problems, a lower starting dose of Halaven is recommended.

Most Common Side Effects
The most common side effects reported ingreater than or equal to25% of
patients receiving Halaven were low white blood cells (82%), low red blood
cells (58%), weakness/tiredness (54%), hair loss (45%), numbness, tingling or
burning in the hands and feet (35%), nausea (35%), and constipation (25%). The
most common serious side effects reported in patients receiving Halaven were
neutropenia with or without a fever (4% and 2%, respectively).

For full prescribing information for Halaven, please visit:
http://www.halaven.com/sites/default/files/HALAVEN_full_Prescribing_Information.pdf

Eisai Oncology
Eisai Oncology is dedicated to discovering, developing and producing
innovative oncology therapies that can help make a difference and impact the
lives of patients and their families. This passion for people is part of
Eisai's human health care (hhc) mission, which is to help address unmet
medical needs and to increase the benefits health care provides to patients
and their families. Our commitment to meaningful progress in oncology
research, built on scientific expertise, is supported by a global capability
to conduct discovery and preclinical research, and develop small molecules,
biologic and supportive care agents for cancer across multiple indications.

Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in
the United States in 1997. Since that time, Eisai Inc. has rapidly grown to
become a fully integrated pharmaceutical business. Eisai's key areas of
commercial focus are neurology and oncology. The company serves as the U.S.
pharmaceutical operation of Eisai Co., Ltd., a research-based human health
care (hhc) company that discovers, develops and markets products throughout
the world.

Eisai has a global product creation organization that includes U.S.-based R&D
facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as
well as manufacturing facilities in Maryland and North Carolina. The company's
areas of R&D focus include neuroscience; oncology; vascular, inflammatory and
immunological reaction; and antibody-based programs. For more information
about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that
discovers, develops and markets products throughout the world. Through a
global network of research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the worldwide
healthcare system.

SOURCE Eisai Inc.

Website: http://www.eisai.com
Contact: Media, Laurie Landau, +1-201-746-2510, or Investors, Alex Scott,
+1-201-746-2177, both of Eisai Inc.